{
    "clinical_study": {
        "@rank": "23444", 
        "arm_group": {
            "arm_group_label": "Famitinib", 
            "arm_group_type": "Experimental", 
            "description": "Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent."
        }, 
        "brief_summary": {
            "textblock": "Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and\n      Flt3. Phase I study has shown that the toxicity is manageable.\n\n      The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in\n      patients with advanced or metastatic Gastroenteropancreatic Neuroendocrine Tumor."
        }, 
        "brief_title": "A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor", 
        "completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastroenteropancreatic Neuroendocrine Tumor", 
        "condition_browse": {
            "mesh_term": [
                "Neuroendocrine Tumors", 
                "Intestinal Neoplasms", 
                "Pancreatic Neoplasms", 
                "Stomach Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Unresectable advanced or metastatic, histologically-confirmed, gastroenteropancreatic\n             neuroendocrine tumor. Tumors must be considered well-differentiated grade G1 or grade\n             G2 in accordance with WHO 2010 classification.\n\n          -  Must have at least one measurable disease by RECIST1.1 criteria(tumour lesions \u226510mm\n             in longest diameter, malignant lymph nodes \u226515mm in short axis, scanning layer \u2264 5\n             mm).\n\n          -  First-line therapy or second-line treatment (second-line treatment i.e. chemotherapy\n             or cytokine therapy as first-line treatment failure or resistant patients).\n\n          -  No previously received targeted therapy of gastroenteropancreatic neuroendocrine\n             tumor (such as everolimus, sunitinib, or other tyrosine kinase or VEGF inhibitor\n             treatment).\n\n          -  Age between 18 and 75 years.\n\n          -  ECOG Performance status \u2264 1.\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  Patients with small-cell carcinoma, pheochromocytoma, paraganglioma or Merkel cell\n             carcinoma\n\n          -  Past or suffering from other cancer, but other than cure basal cell carcinoma and\n             cervical carcinoma in situ\n\n          -  Participated in other clinical trials within four weeks\n\n          -  Concurrent therapy with somatostatin analogs(such as octreotide, lanreotide,etc.)\n\n          -  A variety of factors that affect the oral medication (such as inability to swallow,\n             gastrointestinal resection, chronic diarrhea and intestinal obstruction)\n\n          -  Known brain metastases, spinal cord compression, cancer, meningitis, or screening CT\n             or MRI examination revealed brain or leptomeningeal disease\n\n          -  Subjects received surgery, chemotherapy, radiation therapy, cytokines treatment\n             caused the damage has not been restored, the time interval \u2264 4 weeks, and the wound\n             has not completely healed\n\n          -  Participants have inadequate organ and marrow function as defined below:\n\n               -  hemoglobin < 90g/L\n\n               -  platelets <  100\u00d710^9/L\n\n               -  neutrophils <  1.5\u00d710^9/L\n\n               -  total bilirubin \u2265 1.25\u00d7ULN\n\n               -  serum transaminase(ALT and AST ) \u2265 1.5\u00d7ULN (If liver metastases are present,\n                  serum transaminase\u2265 2.5\u00d7ULN)\n\n               -  creatinine clearance rate \u2264 60ml/min\n\n               -  cholesterol \u2265 1.5\u00d7ULN and triglyceride\u2265 2.5 x ULN,\n\n               -  LVEF: < 50% by Color Doppler Ultrasonography\n\n          -  Patients with uncontrollable hypertension after using single agent therapy (systolic\n             blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg). Patients with more than\n             Class I, myocardial ischemia or myocardial infarction, arrhythmia (including QT\n             interval \u2265 450ms for male and 470ms for female) and class I heart failure.\n\n          -  Urine protein \u2265 + + and confirmed the 24-hour urinary protein>1.0 g\n\n          -  Long-term untreated wounds or fractures\n\n          -  Coagulopathy with bleeding tendency (such as active peptic ulcer)\n\n          -  Previous artery / venous thromboembolic events, such as cerebrovascular accident\n             (including transient ischemic attacks), deep vein thrombosis and pulmonary embolism\n\n          -  Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or\n             its analogues; If the prothrombin time international normalized ratio (INR) \u2264 1.5,\n             with the purpose of prevention, the use of small doses of warfarin (1mg orally, once\n             daily) or low-dose aspirin (less than 100mg daily) is allowed\n\n          -  Female: All subjects who are not surgically sterile or postmenopausal must agree and\n             commit to the use of a reliable method of birth control for the duration of the study\n             and for 6 months after the last dose of test article. Child bearing potential, a\n             negative urine or serum pregnancy test result before initiating Famitinib. Male: All\n             subjects who are not surgically sterile or postmenopausal must agree and commit to\n             the use of a reliable method of birth control for the duration of the study and for 6\n             months after the last dose of test article.\n\n          -  Preexisting thyroid dysfunction, even using medical therapy, thyroid function cannot\n             maintain in the normal range\n\n          -  Abuse of psychiatric drugs or dysphrenia\n\n          -  Immunodeficiency: HIV positive, or other acquired immunodeficiency, congenital\n             immunodeficiency, or organ transplantation\n\n          -  Evidence of significant medical illness that in the investigator's judgment will\n             substantially increase the risk associated with the subject's participation in and\n             completion of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01994213", 
            "org_study_id": "FMTN- \u2161- GEPNET"
        }, 
        "intervention": {
            "arm_group_label": "Famitinib", 
            "description": "Famitinib 25 mg p.o. qd", 
            "intervention_name": "Famitinib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Famitinib", 
            "Gastroenteropancreatic Neuroendocrine Tumor", 
            "GEPNET"
        ], 
        "lastchanged_date": "November 19, 2013", 
        "location": {
            "contact": {
                "last_name": "Jinwan Wang, M.D."
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Randomized, Single-arm, Open-label, Multicenter, Phase II Study of Famitinib as First/Second Line Treatment in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor", 
        "overall_contact": {
            "email": "jianghy@shhrp.com", 
            "last_name": "Haoyuan Jiang, Ph.D,M.D", 
            "phone": "+86 21 68868768"
        }, 
        "overall_official": {
            "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
            "last_name": "Jinwan Wang, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Objective Response Rate", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01994213"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progress free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Disease Control Rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "28-day cycle visit until disease progress"
            }, 
            {
                "measure": "Percent of Participants with OS of one year", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Jiangsu HengRui Medicine Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Cancer Institute and Hospital, Chinese Academy of Medical Science", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Jiangsu HengRui Medicine Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}